Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Hypoxia-induced p53 modulates both apoptosis and radiosensitivity via AKT
Katarzyna B. Leszczynska, … , Francesca M. Buffa, Ester M. Hammond
Katarzyna B. Leszczynska, … , Francesca M. Buffa, Ester M. Hammond
Published May 11, 2015
Citation Information: J Clin Invest. 2015;125(6):2385-2398. https://doi.org/10.1172/JCI80402.
View: Text | PDF
Research Article Oncology

Hypoxia-induced p53 modulates both apoptosis and radiosensitivity via AKT

  • Text
  • PDF
Abstract

Restoration of hypoxia-induced apoptosis in tumors harboring p53 mutations has been proposed as a potential therapeutic strategy; however, the transcriptional targets that mediate hypoxia-induced p53-dependent apoptosis remain elusive. Here, we demonstrated that hypoxia-induced p53-dependent apoptosis is reliant on the DNA-binding and transactivation domains of p53 but not on the acetylation sites K120 and K164, which, in contrast, are essential for DNA damage–induced, p53-dependent apoptosis. Evaluation of hypoxia-induced transcripts in multiple cell lines identified a group of genes that are hypoxia-inducible proapoptotic targets of p53, including inositol polyphosphate-5-phosphatase (INPP5D), pleckstrin domain–containing A3 (PHLDA3), sulfatase 2 (SULF2), B cell translocation gene 2 (BTG2), cytoplasmic FMR1-interacting protein 2 (CYFIP2), and KN motif and ankyrin repeat domains 3 (KANK3). These targets were also regulated by p53 in human cancers, including breast, brain, colorectal, kidney, bladder, and melanoma cancers. Downregulation of these hypoxia-inducible targets associated with poor prognosis, suggesting that hypoxia-induced apoptosis contributes to p53-mediated tumor suppression and treatment response. Induction of p53 targets, PHLDA3, and a specific INPP5D transcript mediated apoptosis in response to hypoxia through AKT inhibition. Moreover, pharmacological inhibition of AKT led to apoptosis in the hypoxic regions of p53-deficient tumors and consequently increased radiosensitivity. Together, these results identify mediators of hypoxia-induced p53-dependent apoptosis and suggest AKT inhibition may improve radiotherapy response in p53-deficient tumors.

Authors

Katarzyna B. Leszczynska, Iosifina P. Foskolou, Aswin G. Abraham, Selvakumar Anbalagan, Céline Tellier, Syed Haider, Paul N. Span, Eric E. O’Neill, Francesca M. Buffa, Ester M. Hammond

×

Figure 5

Hypoxia-induced activation of AKT is attenuated by p53/PHLDA3/SHIP-1 signaling.

Options: View larger image (or click on image) Download as PowerPoint
Hypoxia-induced activation of AKT is attenuated by p53/PHLDA3/SHIP-1 sig...
(A–C) Western blotting comparing AKT-S473 phosphorylation in H1299, HCT116 (p53–/–), and WT HCT116 cells, respectively, exposed to hypoxia for the times indicated. (D) Western blotting for antibodies indicated in RKO cells transfected with either p53 or PHLDA3 siRNA and exposed to 8 hours of hypoxia. (E) Representative images of immunofluorescent costaining with anti-PHLDA3 (green) and anti–pAKT-S473 (red) antibodies in H1299 cells transfected with 5xHRE-PHLDA3 or control and exposed to hypoxia for 12 hours. Scale bar: 10 μm. (F) Hypoxic time course for the mean intensity of pAKT-S473 fluorescence per cell in control or PHLDA3-expressing cells from E. The plot shows mean ± SEM (n = 3, 2-way ANOVA test [**P < 0.01]). (G) Western blotting in HCT116 cells exposed to 18 hours of normoxia or hypoxia in the presence or absence of SHIP-1 inhibitor, 3AC. (H) Western blotting in RKO cells exposed to 14 hours of normoxia or hypoxia in the presence or absence of 3AC.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts